Werewolf Therapeutics/$HOWL
1D1W1MYTD1Y5YMAX
Capital at risk
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
- Ticker
- $HOWL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 39
- Headquarters
- Watertown, United States
- Website
- werewolftx.com
HOWL Metrics
BasicAdvanced
$48M
-
-$0.75
0.29
-
Price and volume
Market cap
$48M
Beta
0.29
52-week high
$2.38
52-week low
$0.27
Average daily volume
13M
Financial strength
Current ratio
2.911
Quick ratio
2.796
Interest coverage (TTM)
-5.62%
Profitability
EBITDA (TTM)
-21.921
Gross margin (TTM)
-24.69%
Net profit margin (TTM)
-164.82%
Operating margin (TTM)
-121.78%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-27.39%
Return on equity (TTM)
-119.86%
Valuation
Price to revenue (TTM)
2.238
Price to book
2.93
Price to tangible book (TTM)
2.93
Price to free cash flow (TTM)
-1.559
Free cash flow yield (TTM)
-64.14%
Free cash flow per share (TTM)
-0.63
Growth
Earnings per share change (TTM)
-54.36%
3-year revenue growth (CAGR)
-5.39%
3-year earnings per share growth (CAGR)
-15.79%
What the Analysts think about HOWL
Analyst ratings (Buy, Hold, Sell) for Werewolf Therapeutics stock.
Analyst projections of the future price of Werewolf Therapeutics stock.
HOWL Financial Performance
Revenues and expenses
HOWL Earnings Performance
Company profitability
Upcoming events
No upcoming events
HOWL News
AllArticlesVideos
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Why Werewolf Therapeutics stock exploded higher and what comes next?
Invezz3 weeks ago
One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
Benzinga4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.